G1 Therapeutics, Inc. (GTHX) Forms $19.45 Double Top; Redmile Group Trimmed By $10.75 Million Its Gw Pharmaceuticals Plc (GWPH) Holding

February 14, 2018 - By Jerrie Dane

Redmile Group Llc decreased Gw Pharmaceuticals Plc (GWPH) stake by 23.91% reported in 2017Q3 SEC filing. Redmile Group Llc sold 106,400 shares as Gw Pharmaceuticals Plc (GWPH)’s stock declined 18.00%. The Redmile Group Llc holds 338,536 shares with $34.36 million value, down from 444,936 last quarter. Gw Pharmaceuticals Plc now has $3.54B valuation. The stock decreased 0.02% or $0.02 during the last trading session, reaching $127.32. About 117,370 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since February 14, 2017 and is uptrending. It has outperformed by 15.20% the S&P500.

G1 Therapeutics, Inc. (GTHX) formed double top with $20.03 target or 3.00% above today’s $19.45 share price. G1 Therapeutics, Inc. (GTHX) has $551.32 million valuation. The stock increased 2.10% or $0.4 during the last trading session, reaching $19.45. About 59,931 shares traded. G1 Therapeutics, Inc. (NASDAQ:GTHX) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 28 analyst reports since August 13, 2015 according to SRatingsIntel. Evercore initiated GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Wednesday, August 16. Evercore has “Buy” rating and $154.0 target. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Overweight” rating by Morgan Stanley on Thursday, August 13. The company was maintained on Monday, October 2 by Leerink Swann. The firm has “Buy” rating given on Monday, September 26 by Cantor Fitzgerald. TH Capital initiated it with “Buy” rating and $130 target in Monday, November 30 report. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Bank of America on Tuesday, February 6. Maxim Group maintained the shares of GWPH in report on Thursday, June 8 with “Buy” rating. Leerink Swann maintained the stock with “Buy” rating in Thursday, December 28 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, August 8. The stock has “Buy” rating by Cantor Fitzgerald on Friday, June 3.

Redmile Group Llc increased Invitae Corp stake by 1.30M shares to 2.11 million valued at $19.79M in 2017Q3. It also upped Atara Biotherapeutics Inc (NASDAQ:ATRA) stake by 155,666 shares and now owns 2.89 million shares. Endologix Inc (NASDAQ:ELGX) was raised too.